Background: Vitiligo is a chronic acquired pigmentary disorder of the skin; it results from immunological distruction of functioning melanocytes. The cytokine TNF-α plays a central role in the initiation of melanocyte apoptosis in vitiligo. Single nucleotide polymorphism (SNP) in the promoter region of the gene coding for serum TNF-α may affect its production.
Objective: The aim of this study is to assess serum TNF-α as a risk factor for generalized vitiligo among Iraqi patients and to rule out that polymorphism at the position affects serum TNF-α.
Materials And Methods: This case-control study was conducted at Sulaymaniyah Dermatology Teaching Center (SDTC), Iraq. Serum concentration of TNF-α was measured using enzyme linked immunosorbent assay (ELISA) technique in 80 patients with generalized vitiligo and 40 clinically healthy controls. The amplification refractory mutation system polymerase chain reaction (ARMS-PCR) technique was used for detection of TNF gene polymorphism. TNF-α level correlated with TNF- gene polymorphism. Serum concentration and TNF gene polymorphism have been analyzed in correlation with demographic features and clinical characteristics of patients with generalized vitiligo.
Results: Statistically significant elevation of serum TNF-α seen in patients compared to a control group (-value 0.01). Significantly higher TNF-α level (-value 0.01) found among patients with active generalized vitiligo. Elevated serum levels of TNF-α were significantly associated with both TNFA1 (TNF) allele (value 0.04) and TNFA2 (TNFA) allele (-value 0.03). TNF-α polymorphism was not affected by demographic features and clinical characteristics of patients with generalized vitiligo.
Conclusion: TNF-α in the serum is a risk factor for generalized vitiligo among Iraqi patients. Patients with active vitiligo have a higher serum TNF-α level. No difference was found between serum level of TNF-α with TNF-α polymorphism at position (TNF ). This involves substituting G allele for the A allele.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671505 | PMC |
http://dx.doi.org/10.2147/CCID.S272970 | DOI Listing |
J Cosmet Dermatol
January 2025
Clinical Research Center of the Carolinas, Charleston, South Carolina, USA.
Background: Exosomes are extracellular vesicles, composed of a phospholipid bilayer, that are primarily derived from stem cells. The contents of exosomes can be incorporated into the tissue in which they are introduced, which presents a unique therapeutic option.
Aims: Exosomes have been investigated as a treatment for a number of medical ailments, but the literature supporting these indications is inconclusive.
Melanoma Res
January 2025
Department of Dermatology, Hospital Universitario y Politécnico La Fe.
Vitiligo-like hypopigmentation induced by immune checkpoint inhibitors (ICIs) has been largely associated with improved survival outcomes in metastatic melanoma. However, its development during adjuvant ICI therapy and its role as a prognostic factor in this setting remain unclear. We aimed to describe ICI-induced vitiligo in a cohort of patients with resected stage III melanoma treated with adjuvant ICI and to identify differences in progression-free survival (PFS) and distant metastasis-free survival (DMFS) between those who developed vitiligo and those who did not.
View Article and Find Full Text PDFBr J Health Psychol
February 2025
School of Healthcare Sciences, Cardiff University, Wales, UK.
Objectives: Skin conditions carry a substantial psychological burden but support for patients is limited. Digital technology could support patient self-management; we found preliminary evidence for the effectiveness and acceptability of digital psychological interventions for adults living with skin conditions. We have, therefore, developed a complex digital intervention called MiDerm with patients.
View Article and Find Full Text PDFFront Immunol
January 2025
Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Biological drugs are extensively used to treat various inflammatory diseases, including psoriasis, atopic dermatitis (AD), and rheumatoid arthritis. While generally effective and safe, these therapies have been increasingly associated with secondary development of vitiligo, especially with anti-TNF α and anti-IL17 drugs. Dupilumab, an IL-4 receptor alpha antagonist used in moderate to severe AD, rarely induces vitiligo.
View Article and Find Full Text PDFOxid Med Cell Longev
December 2024
Center for Global Health, Università Cattolica del Sacro Cuore (UCSC), Rome, Italy.
Vitiligo is a skin disease that affects all ethnicities and genders and is characterized by the loss of pigment essentially due to the selective loss of melanocytes. Although it is generally considered a systemic disease associated with polymorphisms in genes involved in the immune response, vitiligo is also considered an oxidative imbalance-associated disease. It represents a multifactorial pathology in which some genetic predisposition and epigenetic factors coupled with some critical biochemical and molecular pathways could play a pivotal role.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!